This study led to the U.S. FDA approval of adjuvant atezolizumab following resection and platinum-based chemotherapy in stage II-IIIA NSCLC with a PD-L1 expression ≥ 1% (56). Here, CD274 is linked to non-small cell lung carcinoma.